Why Pfizer's Post-COVID Future Looks Brighter Than Ever
It's been a rough few years to be a (NYSE: PFE) shareholder. Shares of the big pharma stock are down about 61% from a peak they set in late 2021. That year, the company's COVID-19 vaccine, Comirnaty, racked up $36.8 billion in sales.
In the first half of 2025, Comirnaty sales came in at just $945 million. Sales of Paxlovid, an antiviral treatment for COVID-19, fell 60% year over year to $918 million. Despite sinking demand for Comirnaty and Paxlovid, Pfizer's post-COVID future looks bright.
Image source: Getty Images.
Source Fool.com
Pfizer Inc. Stock
€24.19
2.630%
We see a rather positive sentiment for Pfizer Inc. with 15 Buy predictions and 2 Sell predictions.
As a result the target price of 29 € shows a slightly positive potential of 19.88% compared to the current price of 24.19 € for Pfizer Inc..
